Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Onyx announces data from three carfilzomib studies on RRMM

Onyx announces data from three carfilzomib studies on RRMM

Immunomodulators show promise against multiple myeloma

Immunomodulators show promise against multiple myeloma

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Study may help personalize pain medication management for sickle cell disease patients

Study may help personalize pain medication management for sickle cell disease patients

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

Celgene reports second quarter total revenue of $1.18 billion

Celgene reports second quarter total revenue of $1.18 billion

Thalidomide analog shows promise against sickle cell disease

Thalidomide analog shows promise against sickle cell disease

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting